Matthew Link Sells 21,831 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Matthew Link sold 21,831 shares of the company’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $5.61, for a total transaction of $122,471.91. Following the completion of the sale, the insider now directly owns 663,550 shares of the company’s stock, valued at $3,722,515.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Matthew Link also recently made the following trade(s):

• On Friday, October 18th, Matthew Link sold 20,487 shares of Sight Sciences stock. The shares were sold at an average price of $5.98, for a total transaction of $122,512.26.
• On Wednesday, October 16th, Matthew Link sold 20,734 shares of Sight Sciences stock. The stock was sold at an average price of $5.91, for a total value of $122,537.94.

Sight Sciences Trading Up 2.4 %

NASDAQ:SGHT opened at $5.65 on Wednesday. The company has a market cap of $281.12 million, a P/E ratio of -5.04 and a beta of 2.71. Sight Sciences, Inc. has a twelve month low of $1.04 and a twelve month high of $8.45. The business has a 50 day moving average price of $6.31 and a two-hundred day moving average price of $6.30. The company has a quick ratio of 10.50, a current ratio of 11.01 and a debt-to-equity ratio of 0.33.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, August 1st. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.06. The business had revenue of $21.37 million for the quarter, compared to analyst estimates of $21.32 million. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. During the same quarter in the prior year, the company posted ($0.30) earnings per share. As a group, analysts expect that Sight Sciences, Inc. will post -1 EPS for the current fiscal year.

Institutional Trading of Sight Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. increased its holdings in shares of Sight Sciences by 31.1% during the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock worth $240,000 after acquiring an additional 8,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Sight Sciences by 51.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock valued at $141,000 after purchasing an additional 9,106 shares during the last quarter. Steele Capital Management Inc. acquired a new stake in shares of Sight Sciences during the 2nd quarter worth about $67,000. State Board of Administration of Florida Retirement System bought a new stake in shares of Sight Sciences during the 1st quarter worth about $59,000. Finally, Rhumbline Advisers boosted its holdings in shares of Sight Sciences by 40.1% during the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after buying an additional 11,671 shares during the period. Institutional investors own 55.51% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on SGHT. Citigroup increased their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Friday, August 2nd. Lake Street Capital started coverage on shares of Sight Sciences in a research note on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price target on the stock. Finally, Morgan Stanley increased their price objective on shares of Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.25.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.